Head to Head Analysis: Impel Pharmaceuticals (NASDAQ:IMPL) and Ventyx Biosciences (NASDAQ:VTYX)

Impel Pharmaceuticals (NASDAQ:IMPL – Get Rating) and Ventyx Biosciences (NASDAQ:VTYX – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Institutional & Insider Ownership

63.9% of Impel Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of Ventyx Biosciences shares are held by institutional investors. 6.3% of Impel Pharmaceuticals shares are held by insiders. Comparatively, 49.1% of Ventyx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Impel Pharmaceuticals and Ventyx Biosciences’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Impel Pharmaceuticals	$670,000.00	37.20	-$76.54 million	($4.64)	-0.23
Ventyx Biosciences	N/A	N/A	-$83.75 million	N/A	N/A

Impel Pharmaceuticals has higher revenue and earnings than Ventyx Biosciences.

Risk & Volatility

Impel Pharmaceuticals has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Impel Pharmaceuticals and Ventyx Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Impel Pharmaceuticals	0	1	1	0	2.50
Ventyx Biosciences	0	0	8	0	3.00

Impel Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 1,328.57%. Ventyx Biosciences has a consensus price target of $52.78, suggesting a potential upside of 43.93%. Given Impel Pharmaceuticals’ higher possible upside, equities analysts plainly believe Impel Pharmaceuticals is more favorable than Ventyx Biosciences.

Profitability

This table compares Impel Pharmaceuticals and Ventyx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Impel Pharmaceuticals	-1,313.87%	-701.26%	-91.67%
Ventyx Biosciences	N/A	-31.24%	-29.07%

Summary

Ventyx Biosciences beats Impel Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Impel Pharmaceuticals

(Get Rating)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

About Ventyx Biosciences

(Get Rating)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.